David Joseph Gaffin, the Executive Vice President and Chief Legal Officer of Alkermes plc, has sold 2,035 shares of the company on November 3, 2026. This transaction is significant as it highlights the ongoing management activities within the pharmaceutical sector.

About Alkermes

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines for the treatment of central nervous system diseases. The company is listed under the ticker ALKS and operates in the pharmaceutical preparations sector.

Details of the Filing

According to the recent filing (accession number 0001520262-26-000133), the transaction was executed at a price of $46.17 per share. Following this sale, Gaffin retains ownership of 219,353 shares in Alkermes. The filing notes that this sale was conducted under a Rule 10b5-1 trading plan that Gaffin adopted on November 19, 2025.

Impact of the Sale

This sale may affect perceptions of Alkermes among investors and analysts, as insider transactions can often be scrutinized for indications of company performance or management confidence. However, it is important to note that the sale was part of a pre-established trading plan, which is designed to avoid any appearance of insider trading.

What's Next?

The filing does not say what happens next.

Reporting Owner Information

David Joseph Gaffin is identified as the Executive Vice President and Chief Legal Officer of Alkermes, Inc. His address is listed as 900 Winter Street, Waltham, MA 02451. The filing indicates that he is an officer of the company, which adds to the relevance of his insider transactions.

Company Background

Alkermes plc operates under the Central Index Key (CIK) number 0001520262 and is classified under the Standard Industrial Classification (SIC) code for Pharmaceutical Preparations [2834]. The company is based in Dublin, Ireland, with its business address at Connaught House, 1 Burlington Road, Dublin 4, L2.

Legal and Compliance Context

The transaction was filed under Form 4, which is used to report changes in ownership of securities by insiders. This filing is part of compliance with the SEC Act of 1934, ensuring transparency in insider trading activities.

Signature and Representation

The filing was signed by Shantale Greenson, who is acting as the attorney-in-fact for David Joseph Gaffin. This indicates that the transaction was formally authorized and complies with legal requirements.